When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy ...

One of the biggest take-aways from our report is that LGBTQ+ people are probably at higher risk for cancer, yet experience ...

Moderna's mRESVIA has secured FDA approval to protect adults ages 60 years and older from lower respiratory tract disease ...

While Canada’s largest vaccine manufacturing facility has opened its doors and is flying the Sanofi flag, another of the ...

Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the ...

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytruda ...

In the U.S., the FDA has pushed its decision date back three months to Sept. 27. Meanwhile in Europe, the Committee for Medicinal Products for Human Use (CHMP) has recommended Dupixent for approval to ...

With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed ...

Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than ...

In the span of half a year, Gilead’s Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer ...

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much ...

Novo Nordisk is standing its ground after the Senate’s Health, Education, Labor and Pensions (HELP) committee recently ...